Quick answer: The most predictive longevity biomarkers are not found on a standard annual physical — VO2max (top 25% vs. bottom 25% = 5-fold difference in all-cause mortality), HOMA-IR insulin resistance index (below 1.0 is optimal vs. conventional “normal” up to 2.5), ApoB lipoprotein (predicts cardiovascular risk 3× more accurately than LDL-C), grip strength (strongest predictor of functional aging and mortality after age 65), and fasting insulin below 5 μIU/mL. This comprehensive guide covers the 15 biomarkers with the strongest evidence for predicting healthspan and lifespan, the optimal reference ranges that most labs do not use, and the interventions that most effectively move each marker in the right direction.
Why Standard Lab Panels Miss Longevity
The typical annual blood panel — CBC, comprehensive metabolic panel, lipid panel, TSH — was designed to detect established disease, not to predict or prevent it. Standard reference ranges are set at the 2.5th to 97.5th percentile of the population being tested, meaning that a result can be “normal” while placing an individual in the worst metabolic quartile for longevity. A fasting insulin of 20 μIU/mL is within the conventional reference range at most labs (reference up to 24-25 μIU/mL) but is associated with severe insulin resistance and a substantially elevated cardiovascular and cancer risk. LDL cholesterol of 130 mg/dL is classified as “borderline” high but tells us almost nothing about atherogenic particle risk without ApoB or LDL-P quantification.
Longevity medicine — influenced heavily by Peter Attia, Rhonda Patrick, David Sinclair, and the research of the National Institute on Aging — has identified a distinct set of biomarkers that predict not just survival but the quality and length of the healthspan: the years lived free of chronic disease and functional decline. These markers cluster into five functional domains: metabolic health, cardiovascular risk, musculoskeletal function, inflammatory burden, and biological age. Optimizing across all five domains simultaneously is the evidence-based approach to extending healthspan.
Domain 1: Metabolic Health Biomarkers
Fasting insulin is the single most important and most underutilized metabolic longevity biomarker. Conventional reference ranges allow fasting insulin up to 24-25 μIU/mL; functional medicine optimizes to below 5 μIU/mL, with below 8 μIU/mL as the minimum acceptable target. Elevations above 10 μIU/mL in the fasting state indicate compensatory hyperinsulinemia — the pancreas working overtime to overcome insulin resistance — and predict development of type 2 diabetes, cardiovascular disease, and some cancers years to decades before HbA1c elevates. Fasting insulin is a 10-year early warning system that most patients have never had ordered.
HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) = (fasting insulin μIU/mL × fasting glucose mg/dL) ÷ 405. Optimal: below 1.0. Insulin resistant: above 2.5. Severely insulin resistant: above 5.0. HOMA-IR integrates both insulin and glucose to quantify the degree of insulin resistance and is more informative than either alone. An individual with normal fasting glucose (90 mg/dL) but elevated fasting insulin (15 μIU/mL) has HOMA-IR of 3.3 — indicating significant insulin resistance — while appearing completely normal on a standard lab panel that does not include insulin.
HbA1c (glycated hemoglobin) reflects average blood glucose over the preceding 2-3 months. Conventional normal is below 5.7%. Longevity-optimized target is below 5.3%, with below 5.0% representing exceptional metabolic health. HbA1c above 5.4% is associated with a graded increase in cardiovascular mortality in multiple large cohort studies — a threshold well below the diabetes cutoff of 6.5%. The limitation of HbA1c is that it misses glucose variability: two individuals with identical HbA1c can have dramatically different glucose spike patterns, and postprandial spikes above 140 mg/dL drive oxidative stress and glycation independently of fasting averages. Continuous glucose monitoring provides the glucose variability data that HbA1c cannot.
Triglyceride:HDL ratio is the most accessible proxy for insulin resistance and atherogenic dyslipidemia when advanced lipid testing is not available. Optimal: below 1.0 (using mg/dL values). Above 3.5 indicates significant metabolic dysfunction. This ratio reflects hepatic VLDL overproduction (driven by insulin resistance and excess carbohydrate/fructose) and reduced HDL from the same mechanism. Normalization of this ratio to below 1.0 requires visceral fat reduction, carbohydrate moderation, triglyceride-lowering interventions (omega-3 at 2-4g EPA+DHA, niacin, fibrates if needed), and resistance exercise.
Uric acid is an underappreciated metabolic longevity marker. Beyond its role in gout, elevated uric acid (above 5.5 mg/dL in women, above 6.0 mg/dL in men) is mechanistically linked to hypertension (uric acid inhibits endothelial nitric oxide synthase), insulin resistance, non-alcoholic fatty liver disease, and cognitive decline. Fructose is the primary dietary driver — fructose metabolism generates uric acid as a direct byproduct, unlike glucose. The rising prevalence of hyperuricemia tracks with increased consumption of high-fructose corn syrup, fruit juice, and ultra-processed foods. Target: below 5.0 mg/dL for longevity optimization.
Domain 2: Cardiovascular Longevity Biomarkers
ApoB (apolipoprotein B) is the most important single cardiovascular biomarker for longevity assessment. Every atherogenic lipoprotein particle — LDL, VLDL, IDL, Lp(a) — carries exactly one ApoB molecule. ApoB therefore directly quantifies the total number of atherogenic particles in circulation, which is the actual mechanistic driver of atherosclerotic plaque development. LDL cholesterol, in contrast, measures the cholesterol content within LDL particles but says nothing about particle number — a patient can have low LDL-C with high ApoB (many small, cholesterol-poor LDL particles) and be at high cardiovascular risk while appearing low-risk on a standard lipid panel. Optimal ApoB: below 60 mg/dL for high-risk individuals; below 80 mg/dL as a general longevity target. Conventional reference range (below 130 mg/dL) is grossly inadequate for longevity optimization.
Lp(a) (lipoprotein(a)) is genetically determined in 80-90% of its variance and represents the most underdiagnosed cardiovascular risk factor in clinical practice. Elevated Lp(a) — above 30-50 nmol/L, or above 30 mg/dL depending on assay — is present in approximately 20% of the population and independently doubles cardiovascular risk regardless of LDL level. It is prothrombotic (Lp(a) carries oxidized phospholipids and has structural similarity to plasminogen, interfering with fibrinolysis) and pro-inflammatory. Every adult should know their Lp(a) once, as it is largely stable throughout life. Currently, no approved pharmacotherapy specifically lowers Lp(a), though PCSK9 inhibitors reduce it 15-20%, and investigational RNA therapies (pelacarsen, olpasiran) show 80-90% reductions in trials. If elevated, aggressive optimization of all modifiable cardiovascular risk factors is warranted.
hs-CRP (high-sensitivity C-reactive protein) below 0.5 mg/L is the longevity optimization target — conventional “normal” is below 3.0 mg/L, and “low risk” is below 1.0 mg/L, but the evidence from the JUPITER trial and multiple large cohort studies shows that hs-CRP below 0.5 mg/L is associated with markedly lower cardiovascular and cancer mortality than levels of 1-3 mg/L. Chronic low-grade inflammation is a driver of all major age-related diseases, and hs-CRP is its most accessible systemic marker. Key interventions for normalization: omega-3 fatty acids 3-4g EPA+DHA daily, Mediterranean-style diet, elimination of ultra-processed foods, Zone 2 exercise, weight reduction (particularly visceral fat), and treatment of any underlying infections (dental, periodontal, gut dysbiosis).
Homocysteine at optimal levels below 8 μmol/L (vs. conventional normal below 15 μmol/L) predicts cardiovascular disease, cognitive decline, and dementia independently of traditional risk factors. The Rotterdam Study (n=7,983) found that homocysteine above 10 μmol/L was associated with doubled dementia risk. B vitamins — methylfolate 400-800 mcg, methylcobalamin 1,000 mcg, P5P 25-50 mg, and riboflavin 25 mg — reduce homocysteine 25-30% in most individuals. MTHFR variants (present in 50-60% of the population) impair the methylation cycle and produce chronically elevated homocysteine that responds poorly to folic acid but well to methylated B vitamins.
Domain 3: The Single Most Powerful Longevity Biomarker — VO2max
VO2max — maximal oxygen uptake, expressed as mL O2/kg/min — has emerged from the past decade of research as the single most powerful predictor of all-cause mortality. The landmark Kokkinos 2022 study (n=750,302 veterans, median follow-up 10.1 years) demonstrated that comparing individuals in the lowest fitness quintile to the highest fitness quintile produced a relative risk reduction in all-cause mortality of 4-5 fold — a magnitude of effect greater than any medication, any diet intervention, or any other lifestyle factor studied to date. This is not a modest association; it is an overwhelming physiological signal.
Going from “low” to “below average” fitness (just one quintile improvement) reduced mortality risk by 50% — a reduction comparable to quitting smoking. The dose-response relationship is continuous with no plateau, meaning the highest fitness individuals have progressively lower mortality risk at every level of comparison. VO2max declines approximately 10% per decade after age 30 without intervention, and 1% per year accelerates to 2-3% per year after 70. Interventions that attenuate this decline — Zone 2 training, high-intensity interval training, resistance training — are among the highest-yield longevity investments available.
VO2max reference ranges by age and sex (in mL/kg/min):
For longevity optimization, the target is the “Superior” category for age: Men aged 40-49: above 46.4; Men aged 50-59: above 43.4; Men aged 60-69: above 36.5. Women aged 40-49: above 39.5; Women aged 50-59: above 35.7; Women aged 60-69: above 31.4. Below “Below Average” for age is where mortality risk rises sharply. Testing options: formal VO2max test in a sports performance lab (gold standard), cardiopulmonary exercise testing (CPET), or estimated VO2max from resting heart rate and heart rate recovery calculations on most modern fitness trackers (within 10-15% accuracy).
The most effective protocol for VO2max improvement: The polarized training model — 80% Zone 2 (sustainable aerobic, first lactate threshold, 60-70% max HR), 20% high-intensity intervals — produces the greatest VO2max improvement over 12-24 weeks in non-elite athletes. Seiler’s research on polarized vs. threshold training showed superior VO2max adaptation with the polarized approach. Minimum effective dose for meaningful VO2max improvement: 150 minutes Zone 2 per week plus 2 HIIT sessions (4-6 × 4-minute intervals at 90-95% max HR with equal rest periods).
Domain 4: Musculoskeletal Longevity Markers
Grip strength is the most accessible and most validated musculoskeletal longevity biomarker. The PURE study (n=139,691 across 17 countries) found that grip strength was a stronger predictor of cardiovascular mortality than systolic blood pressure. The Biobank UK cohort (n=500,000+) confirmed grip strength as one of the top independent predictors of all-cause mortality. Grip strength integrates whole-body musculoskeletal health — it reflects both upper body strength and systemic neuromuscular function. Optimal: men above 45 kg (approximately 99 lbs), women above 30 kg (66 lbs) using a hand dynamometer; these are 75th percentile values for ages 40-59. Measurement is inexpensive (dynamometers available for under $30), reproducible, and tracks longitudinal change.
Lean muscle mass / skeletal muscle index — assessed by DEXA scan or bioelectrical impedance — tracks sarcopenia risk. Sarcopenia (age-related muscle loss) affects 10% of adults aged 60-69 and 50% above age 80, and is an independent predictor of falls, fractures, metabolic dysfunction, and mortality. The skeletal muscle index (SMI) = appendicular lean mass (kg) ÷ height² (m²). Optimal SMI: men above 8.87 kg/m², women above 6.42 kg/m² (FNIH Sarcopenia Project criteria). Resistance training 2-3 times per week with progressive overload is the primary intervention, combined with protein intake at 1.6-2.2 g/kg body weight per day (substantially above the RDA of 0.8 g/kg which was set to prevent deficiency, not to optimize muscle maintenance).
Bone mineral density (DEXA T-score) predicts fracture risk and functional longevity. The T-score of 0 or above represents peak bone mass; osteopenia begins at -1.0; osteoporosis at -2.5. Hip fracture in adults above 65 carries a 30-day mortality of approximately 5-10% and a one-year mortality of 15-30% — making bone density one of the most consequential longevity biomarkers in the second half of life. Modifiable factors: vitamin D (target 50-70 ng/mL), calcium intake (dietary preferred over supplementation), weight-bearing exercise, resistance training, estrogen and testosterone status, and avoidance of bone-depleting medications (proton pump inhibitors reduce calcium absorption 20-40% with long-term use).
Domain 5: Hormonal and Nutritional Longevity Markers
Vitamin D (25-hydroxyvitamin D) — optimal 50-70 ng/mL versus conventional sufficiency of above 30 ng/mL. Vitamin D deficiency (below 20 ng/mL) is present in over 40% of US adults and is associated with increased all-cause mortality in multiple large meta-analyses. The Mendelian randomization data from Afzal 2014 (BMJ, n=95,766) showed genetic variants predicting lower vitamin D associated with higher cardiovascular mortality — supporting a causal relationship rather than confounding. At the 50-70 ng/mL optimal range, vitamin D functions as a hormone (VDR receptors are expressed in nearly every cell type) with documented roles in immune regulation, inflammation reduction, insulin sensitivity, neurocognitive function, and cancer risk reduction.
Testosterone (total and free) — free testosterone is the biologically active fraction, and decline in free testosterone — which begins in the late 30s and accelerates after 50 — is associated with sarcopenia, metabolic syndrome, cognitive decline, depression, and cardiovascular risk. Total testosterone can be misleading if sex hormone-binding globulin (SHBG) is elevated (sequestering free testosterone). Optimal total testosterone: men 600-900 ng/dL (vs. conventional reference 300-1,000+ ng/dL); free testosterone above 15 ng/dL. For women, total testosterone 50-100 ng/dL and free testosterone above 5 pg/mL. Low testosterone in both sexes is a significant modifiable longevity risk factor addressable through resistance training, sleep optimization, visceral fat reduction, and when indicated, hormone replacement therapy.
IGF-1 (insulin-like growth factor 1) has a complex relationship with longevity. Higher IGF-1 supports muscle mass, bone density, and cognitive function, but very high IGF-1 is associated with increased cancer risk (particularly breast, prostate, and colorectal). The optimal range for longevity appears to be the mid-normal range for age: 100-200 ng/mL for adults aged 40-60. Below 80 ng/mL reflects growth hormone deficiency and sarcopenia risk; above 250 ng/mL raises cancer concern. IGF-1 is modulated by protein intake (high protein, particularly leucine-rich amino acids, raises IGF-1), exercise (both resistance and aerobic training raise IGF-1), and sleep quality (80% of growth hormone is secreted during deep sleep, driving IGF-1 production).
DHEA-S is both a marker of adrenal reserve and an independent longevity predictor. The MacArthur Study of Successful Aging found that higher DHEA-S was one of the strongest predictors of maintained physical and cognitive function in men aged 70-79. DHEA-S declines 70-80% from peak levels (age 20-30) to old age, and low DHEA-S is associated with all-cause mortality in multiple prospective studies. Optimal: 150-350 mcg/dL for women, 300-500 mcg/dL for men aged 40-60. Correction of HPA axis dysregulation (which drives pregnenolone toward cortisol at DHEA’s expense) is the root-cause intervention; DHEA supplementation is appropriate when confirmed low after HPA optimization.
Biological Age Testing: Epigenetic Clocks
Epigenetic clocks — methylation-based biological age calculations from blood DNA — represent the most exciting and rapidly evolving area of longevity biomarker science. The original Horvath clock (2013) used DNA methylation at 353 CpG sites to calculate biological age with remarkable accuracy. Newer clocks — PhenoAge (Levine 2018), GrimAge (Lu 2019), DunedinPACE (Belsky 2022) — incorporate phenotypic and clinical data to predict remaining healthspan and rate of aging rather than just biological age.
GrimAge in particular has shown outstanding predictive validity: a 1-year acceleration in GrimAge age was associated with a 17% higher risk of death in the original validation cohort, independent of chronological age. DunedinPACE (Dunedin Study Pace of Aging Calculated from the Epigenome) measures the rate of biological aging — whether the body is aging at 0.8 years per year (slower than normal) or 1.2 years per year (faster than normal) — making it a powerful intervention monitor. The Rejuvant trial by Fitzgerald 2021 demonstrated 3.23-year reduction in biological age after 8 weeks of a comprehensive lifestyle protocol — the first RCT to show reversal of epigenetic age.
Commercial epigenetic age testing is available through TruMe, Elysium Index, and TallyHealth (Horvath-based), with price points of $200-500 per test. These are most valuable for tracking biological age change in response to interventions over 6-12 month intervals rather than as one-time snapshot assessments. The most robust finding across all studies is that the lifestyle factors most powerfully reducing biological age are: quality sleep (7-9 hours), Zone 2 aerobic exercise, dietary quality (Mediterranean and minimally processed food patterns), stress management, and avoidance of smoking and excess alcohol.
The Complete Longevity Biomarker Panel: What to Order
For a comprehensive annual longevity assessment, the following panel covers all five domains with optimal cost-effectiveness. This can be ordered through functional medicine providers, direct-to-consumer lab services (Marek Diagnostics, Function Health, Ulta Lab Tests), or requested from primary care physicians.
Metabolic domain: Fasting insulin, fasting glucose, HbA1c, HOMA-IR (calculated), comprehensive metabolic panel (for kidney function, liver enzymes), uric acid, complete blood count.
Cardiovascular domain: Advanced lipid panel (ApoB, LDL-P, HDL-P, LDL particle size), Lp(a) — once per lifetime is sufficient unless intervention, hs-CRP, homocysteine, fibrinogen, NMR LipoProfile or VAP.
Hormonal domain: Total and free testosterone (with SHBG), DHEA-S, IGF-1, cortisol morning (or 4-point salivary for pattern), complete thyroid panel (TSH, free T3, free T4, reverse T3, TPO-Ab), vitamin D (25-OH), estradiol and progesterone (cycle day 19-21 for premenopausal women).
Inflammatory domain: hs-CRP, ferritin (dual role as iron marker and acute phase reactant), ESR, oxidized LDL if available, omega-3 index (target above 8%).
Nutritional domain: Vitamin D, B12 (methylmalonic acid for functional deficiency), folate, magnesium RBC (more sensitive than serum), zinc, ferritin + iron saturation.
Functional testing (beyond blood): VO2max assessment (exercise test or fitness tracker estimation), grip strength (dynamometer), DEXA scan (body composition and bone density) every 2-3 years after age 40, continuous glucose monitoring 2-week wear annually for glucose variability assessment.
Frequently Asked Questions
What is the single most important longevity biomarker?
VO2max has the largest effect size for all-cause mortality prediction in the published literature — a 5-fold difference in mortality between the highest and lowest fitness quintiles in the Kokkinos 2022 trial of 750,302 veterans. No medication, diet, or supplement comes close to this magnitude of risk reduction. However, VO2max is a functional measure rather than a blood biomarker. Among blood biomarkers, ApoB (for cardiovascular risk), fasting insulin (for metabolic disease risk), and DHEA-S (for HPA reserve and biological aging) collectively provide the most predictive information about longevity risk across the major disease categories that drive premature mortality.
What fasting insulin level is optimal for longevity?
Optimal fasting insulin for longevity is below 5 μIU/mL. Below 8 μIU/mL is a reasonable minimum acceptable target. Conventional reference ranges allow fasting insulin up to 24-25 μIU/mL, which is far too permissive for longevity optimization. Fasting insulin above 10 μIU/mL indicates compensatory hyperinsulinemia — the pancreas overproducing insulin to overcome insulin resistance — and predicts development of type 2 diabetes, cardiovascular disease, and certain cancers years to decades before HbA1c or fasting glucose elevates. Most adults will normalize fasting insulin to below 8 μIU/mL through carbohydrate reduction, elimination of liquid calories, time-restricted eating (early eating window), resistance exercise, and visceral fat reduction.
Is ApoB better than LDL for predicting heart disease?
Yes — ApoB is consistently superior to LDL-C for cardiovascular risk prediction in multiple large studies. The AMORIS study (n=175,553) demonstrated that ApoB predicted myocardial infarction better than LDL-C in both sexes. The disagreement between LDL-C and ApoB is most common in insulin-resistant individuals with metabolic syndrome, who often have “normal” or even low LDL-C while having high ApoB from large numbers of small, dense, cholesterol-poor LDL particles. These patients are systematically misclassified as low cardiovascular risk by LDL-C while being high risk by particle-based measures. Optimal ApoB for longevity: below 60-70 mg/dL.
How often should longevity biomarkers be tested?
The optimal cadence: comprehensive baseline panel at initiation (including all domains above); repeat annually for metabolic, cardiovascular, hormonal, and inflammatory markers; DEXA scan every 2-3 years after age 40 (or annually if actively working on body composition); Lp(a) once in a lifetime (it does not change significantly except with PCSK9 inhibitor therapy); epigenetic age testing every 6-12 months if actively monitoring biological age interventions. After significant lifestyle changes (major dietary shift, new exercise program, weight loss of more than 10%), retesting at 3-6 months provides motivating feedback on the biomarker response to intervention.
Longevity medicine is actionable medicine — every biomarker in this panel has at least one evidence-based intervention that moves it in the right direction. If you would like a comprehensive longevity biomarker evaluation, personalized interpretation of your results against functional reference ranges, and a prioritized intervention protocol, Dr. Tom Biernacki and The Private Practice offer complete functional longevity assessments. Call (810) 206-1402 to schedule your consultation and get your first complete longevity panel with functional interpretation.
Related Articles
- Zone 2 Training & Longevity: The Evidence
- NAD+, NMN & NR Supplements: The Science
- Optimal Vitamin D Levels: What the Research Shows